73075-47-5

Usage

Uses

Used in Pharmaceutical Research:
5,7-Di-Chloro-1,2,3,4-tetrahydroisoquinoline HCL is utilized as a reagent in organic synthesis and pharmaceutical research for its potential to contribute to the development of new therapeutic agents.
Used in Central Nervous System Disorders:
In the field of medicine, 5,7-Di-Chloro-1,2,3,4-tetrahydroisoquinoline HCL is used as a pharmacological agent for the treatment of central nervous system disorders, leveraging its potential neuromodulatory effects.
Used in Pain Management:
5,7-Di-Chloro-1,2,3,4-tetrahydroisoquinoline HCL is also employed in pain management applications, where its properties may contribute to the alleviation of pain symptoms.
Used as a Precursor in Drug Synthesis:
5,7-Di-Chloro-1,2,3,4-tetrahydroisoquinoline HCL is used as a precursor in the synthesis of various pharmaceutical drugs, indicating its importance in the development of new medications.
Used in the Synthesis of Heterocyclic Compounds:
Furthermore, 5,7-Di-Chloro-1,2,3,4-tetrahydroisoquinoline HCL is a valuable building block for the synthesis of a diverse range of heterocyclic compounds, which possess potential biological activities and can be applied in various therapeutic areas.

InChI:InChI=1/C9H9Cl2N.ClH/c10-7-3-6-5-12-2-1-8(6)9(11)4-7;/h3-4,12H,1-2,5H2;1H

Upstream product

• 2905-62-6 3,5-dichlorobenzoyl chloride 
• 344307-65-9 3,5-dichloro-N-(2-hydroxyethyl)benzamide 
• 10203-08-4 3,5-dichlorobenzaldehyde 
• 73075-58-8 5,7-dichloro isoquinoline 
• 1000210-73-0 (3,5-dichloro-benzylidene)-(2,2-diethoxy-ethyl)-amine 

Downstream Products

• 1289646-72-5 C₂₈H₂₃Cl₂N 
• 851784-82-2 2-(tert-butoxycarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 
• 1194550-63-4 C₄₆H₄₀Cl₂N₂O₅S 
• 1194550-56-5 5,7-dichloro-2-trityl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 
• 1025967-78-5 (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid 
• 1289646-93-0 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid hydrochloride 

Relevant academic research and scientific papers

Scalable Process for Making 5,7-Dichlorotetrahydroisoquinoline-6-carboxylic Acid Using Methylene as the Protecting Group

The development of an industrially scalable synthetic route for 5,7-dichlorotetrahydroisoquinoline-6-carboxylic acid (1), a key starting material for lifitegrast, is described. This route includes the following features: (1) tetrahydroisoquinoline19was pr

Synthesis method of 5, 7-dichloro-1, 2, 3, 4-tetrahydroisoquinoline hydrochloride

The invention relates to a synthesis method of 5, 7-dichloro-1, 2, 3, 4-tetrahydroisoquinoline hydrochloride, and belongs to the technical field of synthesis of medical intermediates. The method comprises the steps that 3, 5-dichlorobenzaldehyde serves as a raw material, 5, 7-dichloro-1, 2, 3, 4-tetrahydroisoquinoline hydrochloride is obtained through Schiff base preparation, reduction, ring closing and reductive acidification reaction, and the total yield is 60% or above. The method avoids using expensive raw materials, and is simple in process route, mild in condition, low in production costand suitable for industrial production.

Synthesis method of lifitegrast intermediate 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline

The invention discloses a synthesis method of a lifitegrast intermediate 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline, wherein the synthesis method comprises the steps: by using 2,4-dichlorobenzaldehyde as a starting material, carrying out nitro-alcohol co

LFA-1 INHIBITOR AND POLYMORPH THEREOF

Methods of preparation and purification of a compound, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA -1 mediated diseases are also disclosed.